While its announcement of a new low-cost sequencing platform caused one blogger to lose some sleep, Illumina has Forbes' Matthew Herper contemplating the consequences of the Life Technologies Ion Personal Genome Machine's new competition within the sequencing market.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.